Alnylam’s full analysis of its clinical trial data for an experimental treatment known as givosiran — a drug candidate from the company that relies on a Nobel prize-winning gene-silencing technique — shows more promise for some patients than others.
The analysis, which the company presented Friday at the annual meeting of the European Association for the Study of the Liver (EASL), is a more complete version of the topline data that the company released in March and looks at patients with acute intermittent porphyria, a rare disease that can cause acute and sometimes life-threatening attacks.
About the Author Reprints
